Managed care organizations join to bring strength and stability to North Carolina’s public system of behavioral healthcare Today, North Carolina Department of Health and Human Services Secretary ...
NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other ...
(Nasdaq: AGAE) (“AIFA” or the “Company”) today announced that the Company has entered into a package of transaction definitive agreements to acquire an aggregate 57.67% controlling interest in ...
As more than 440,000 Camp Lejeune Justice Act (CLJA) claims remain gridlocked between the trial litigation in the U.S.
Mission Produce, Inc. (NASDAQ: AVO) (“Mission Produce”) and Calavo Growers, Inc. (NASDAQ: CVGW) (“Calavo”), today announced, in connection with Mission Produce’s pending acquisition of Calavo, that ...
AriseAlpha today announced the launch of its free AI-Powered Automated Investing Platform, equipped with advanced AI trading ...
Skyworks Solutions, Inc. (Nasdaq: SWKS) (“Skyworks”), a leading developer, manufacturer and provider of analog and mixed-signal semiconductors and solutions for numerous applications, today announced ...
Energy, Inc. (NASDAQ: XE) (“X-energy” or the “Company”), a leading designer of advanced nuclear reactor technology and manufacturer of nuclear fuels, today announced it plans to report first quarter ...
SEALSQ Corp (NASDAQ: LAES) ("SEALSQ" or "Company"), a company that focuses on developing and selling Semiconductors, PKI, and ...
Prairie Operating Co. (Nasdaq: PROP) (the “Company” or “Prairie”), an independent energy company engaged in the development and acquisition of oil and natural gas resources in the Denver-Julesburg (DJ ...
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) disorders ...
Preliminary mPFS of 15.2 months; mDOR not reachedRobust CNS activity, with 86% CNS ORR; no patients developed de novo brain metastasesORR 60% in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results